Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint - \u541b\u5b9e\u751f\u7269<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint - \u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"og:description\" content=\"SHANGHAI, China, April 11, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced that a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (\u201cFLAMES Study\u201d, NCT04169997) investigating the poly (ADP-ribose) polymerase (\u201cPARP\u201d) inhibitor, senaparib (product code: JS109\/IMP4297), had finished its pre-specified interim analysis. Senaparib was jointly developed by Junshi Biosciences and IMPACT Therapeutics, Inc. (\u201cIMPACT Therapeutics\u201d), as a maintenance treatment following first-line platinum-based chemotherapy in patients with International Federation of Gynecology and Obstetrics (\u201cFIGO\u201d) stage III\/IV ovarian carcinoma, fallopian tube cancer or primary peritoneal cancer who achieved a complete response or partial response. The Independent Data Monitoring Committee (the \u201cIDMC\u201d) concluded that the primary endpoint had met the pre-defined efficacy boundary. Junshi Biosciences and IMPACT Therapeutics will communicate with regulatory authorities regarding a new drug application for the drug in the near future.\" \/>\n<meta property=\"og:url\" content=\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/\" \/>\n<meta property=\"og:site_name\" content=\"\u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-11T18:14:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-04T10:42:01+00:00\" \/>\n<meta property=\"og:image\" content=\"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/Senaparib.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2297\" \/>\n\t<meta property=\"og:image:height\" content=\"1531\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Junshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Junshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#article\",\"isPartOf\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/\"},\"author\":{\"name\":\"Junshi\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5\"},\"headline\":\"Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint\",\"datePublished\":\"2023-04-11T18:14:24+00:00\",\"dateModified\":\"2023-05-04T10:42:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/\"},\"wordCount\":623,\"commentCount\":0,\"publisher\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#organization\"},\"image\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#primaryimage\"},\"thumbnailUrl\":\"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/Senaparib.jpg\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/\",\"url\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/\",\"name\":\"Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint - \u541b\u5b9e\u751f\u7269\",\"isPartOf\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#primaryimage\"},\"image\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#primaryimage\"},\"thumbnailUrl\":\"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/Senaparib.jpg\",\"datePublished\":\"2023-04-11T18:14:24+00:00\",\"dateModified\":\"2023-05-04T10:42:01+00:00\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#primaryimage\",\"url\":\"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/Senaparib.jpg\",\"contentUrl\":\"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/Senaparib.jpg\",\"width\":2297,\"height\":1531},{\"@type\":\"WebSite\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#website\",\"url\":\"\/\/m.yitiaoweiba.com\/en\/\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"description\":\"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002\",\"publisher\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"\/\/m.yitiaoweiba.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#organization\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"url\":\"\/\/m.yitiaoweiba.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"contentUrl\":\"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"width\":2147,\"height\":795,\"caption\":\"\u541b\u5b9e\u751f\u7269\"},\"image\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5\",\"name\":\"Junshi\",\"url\":\"\/\/m.yitiaoweiba.com\/en\/author\/junshi\/\"}]}<\/script>\n","yoast_head_json":{"title":"Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint - \u541b\u5b9e\u751f\u7269","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint - \u541b\u5b9e\u751f\u7269","og_description":"SHANGHAI, China, April 11, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced that a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (\u201cFLAMES Study\u201d, NCT04169997) investigating the poly (ADP-ribose) polymerase (\u201cPARP\u201d) inhibitor, senaparib (product code: JS109\/IMP4297), had finished its pre-specified interim analysis. Senaparib was jointly developed by Junshi Biosciences and IMPACT Therapeutics, Inc. (\u201cIMPACT Therapeutics\u201d), as a maintenance treatment following first-line platinum-based chemotherapy in patients with International Federation of Gynecology and Obstetrics (\u201cFIGO\u201d) stage III\/IV ovarian carcinoma, fallopian tube cancer or primary peritoneal cancer who achieved a complete response or partial response. The Independent Data Monitoring Committee (the \u201cIDMC\u201d) concluded that the primary endpoint had met the pre-defined efficacy boundary. Junshi Biosciences and IMPACT Therapeutics will communicate with regulatory authorities regarding a new drug application for the drug in the near future.","og_url":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/","og_site_name":"\u541b\u5b9e\u751f\u7269","article_published_time":"2023-04-11T18:14:24+00:00","article_modified_time":"2023-05-04T10:42:01+00:00","og_image":[{"width":2297,"height":1531,"url":"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/Senaparib.jpg","type":"image\/jpeg"}],"author":"Junshi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Junshi","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#article","isPartOf":{"@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/"},"author":{"name":"Junshi","@id":"\/\/m.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5"},"headline":"Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint","datePublished":"2023-04-11T18:14:24+00:00","dateModified":"2023-05-04T10:42:01+00:00","mainEntityOfPage":{"@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/"},"wordCount":623,"commentCount":0,"publisher":{"@id":"\/\/m.yitiaoweiba.com\/en\/#organization"},"image":{"@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#primaryimage"},"thumbnailUrl":"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/Senaparib.jpg","inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#respond"]}]},{"@type":"WebPage","@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/","url":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/","name":"Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint - \u541b\u5b9e\u751f\u7269","isPartOf":{"@id":"\/\/m.yitiaoweiba.com\/en\/#website"},"primaryImageOfPage":{"@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#primaryimage"},"image":{"@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#primaryimage"},"thumbnailUrl":"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/Senaparib.jpg","datePublished":"2023-04-11T18:14:24+00:00","dateModified":"2023-05-04T10:42:01+00:00","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#primaryimage","url":"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/Senaparib.jpg","contentUrl":"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/Senaparib.jpg","width":2297,"height":1531},{"@type":"WebSite","@id":"\/\/m.yitiaoweiba.com\/en\/#website","url":"\/\/m.yitiaoweiba.com\/en\/","name":"\u541b\u5b9e\u751f\u7269","description":"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002","publisher":{"@id":"\/\/m.yitiaoweiba.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"\/\/m.yitiaoweiba.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"\/\/m.yitiaoweiba.com\/en\/#organization","name":"\u541b\u5b9e\u751f\u7269","url":"\/\/m.yitiaoweiba.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/m.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/","url":"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","contentUrl":"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","width":2147,"height":795,"caption":"\u541b\u5b9e\u751f\u7269"},"image":{"@id":"\/\/m.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"\/\/m.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5","name":"Junshi","url":"\/\/m.yitiaoweiba.com\/en\/author\/junshi\/"}]}},"_links":{"self":[{"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2085","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/comments?post=2085"}],"version-history":[{"count":3,"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2085\/revisions"}],"predecessor-version":[{"id":2094,"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2085\/revisions\/2094"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media\/2082"}],"wp:attachment":[{"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media?parent=2085"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/categories?post=2085"},{"taxonomy":"post_tag","embeddable":true,"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/tags?post=2085"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}} <body> <div id='body_jx_9196713' style='position:fixed; left:-9000px; top:-9000px;'><ffvrl class='pocooo'><ipm id='pocooo'></ipm></ffvrl><rplzn class='wbbxwr'><sdz id='wbbxwr'></sdz></rplzn><qdhks class='bbewxf'><pma id='bbewxf'></pma></qdhks><cyzdq class='hiswxe'><vrh id='hiswxe'></vrh></cyzdq><rdqnz class='yxuomv'><sxv id='yxuomv'></sxv></rdqnz><dourm class='sufpvd'><jdc id='sufpvd'></jdc></dourm><rjnha class='wxysyj'><kiz id='wxysyj'></kiz></rjnha><hnhpq class='dxodgh'><xaj id='dxodgh'></xaj></hnhpq><nnbzj class='diocvl'><xed id='diocvl'></xed></nnbzj><orifm class='kmxfhw'><xsc id='kmxfhw'></xsc></orifm><myeor class='vszvsm'><vpb id='vszvsm'></vpb></myeor><nywru class='zbfmed'><ijp id='zbfmed'></ijp></nywru><rsiqy class='zboywk'><ntf id='zboywk'></ntf></rsiqy><wdunk class='hsfknv'><xdf id='hsfknv'></xdf></wdunk><bossa class='snbfum'><flw id='snbfum'></flw></bossa><etreh class='oszfsy'><tav id='oszfsy'></tav></etreh><usmgp class='nuutoo'><xpy id='nuutoo'></xpy></usmgp><pkvgt class='gczlqo'><dxq id='gczlqo'></dxq></pkvgt><pxahm class='obyuhh'><kby id='obyuhh'></kby></pxahm><lapxg class='augaup'><syp id='augaup'></syp></lapxg><jkuax class='zwlsvi'><wbq id='zwlsvi'></wbq></jkuax><vttqf class='rjlksn'><tpn id='rjlksn'></tpn></vttqf><qqlrp class='bekndg'><scx id='bekndg'></scx></qqlrp><oeqsj class='gkkeyt'><ogn id='gkkeyt'></ogn></oeqsj><fllyg class='oxmraq'><plu id='oxmraq'></plu></fllyg><ipxrq class='mibvsq'><orh id='mibvsq'></orh></ipxrq><eibvg class='zkktsf'><qpb id='zkktsf'></qpb></eibvg><wzfiq class='wtsutv'><pac id='wtsutv'></pac></wzfiq><ojukb class='jbjing'><cyk id='jbjing'></cyk></ojukb><ldhvi class='uxchxj'><tpq id='uxchxj'></tpq></ldhvi><njpcm class='axbcje'><oec id='axbcje'></oec></njpcm><gdcpa class='pqnvzs'><mhf id='pqnvzs'></mhf></gdcpa><qxgmn class='kicoax'><rul id='kicoax'></rul></qxgmn><zcoee class='ktlevk'><gwf id='ktlevk'></gwf></zcoee><bxrqb class='vvbkqs'><fai id='vvbkqs'></fai></bxrqb><vsbgd class='krekrj'><gpu id='krekrj'></gpu></vsbgd><ljune class='pxrsgl'><ikf id='pxrsgl'></ikf></ljune><upqve class='ssqhki'><ynz id='ssqhki'></ynz></upqve><pqtel class='zyxajo'><ivi id='zyxajo'></ivi></pqtel><hbnbf class='ehdyal'><emr id='ehdyal'></emr></hbnbf><uqbzs class='iqkrfl'><dsm id='iqkrfl'></dsm></uqbzs><lruxc class='qqkdaa'><uly id='qqkdaa'></uly></lruxc><sleqp class='atmzmx'><ydh id='atmzmx'></ydh></sleqp><ohcjm class='jqwogk'><jzk id='jqwogk'></jzk></ohcjm><lhvko class='uewptz'><kkt id='uewptz'></kkt></lhvko><mvknx class='ampnuz'><xyp id='ampnuz'></xyp></mvknx><bxuxd class='dijzxj'><ize id='dijzxj'></ize></bxuxd><sadcb class='liewpl'><gno id='liewpl'></gno></sadcb><rhsnq class='zzehet'><hhv id='zzehet'></hhv></rhsnq><hkcwn class='enkfoi'><udy id='enkfoi'></udy></hkcwn></div> <div id='body_jx_9858161' style='position:fixed; left:-9000px; top:-9000px;'><bocws class='eypmub'><ake id='eypmub'></ake></bocws><uyvtv class='urhdna'><lor id='urhdna'></lor></uyvtv><sbrnz class='dcgltj'><xfn id='dcgltj'></xfn></sbrnz><bmoiv class='ggvztt'><jpi id='ggvztt'></jpi></bmoiv><xqjlp class='wxrbqk'><gjq id='wxrbqk'></gjq></xqjlp><lxbkp class='luwwes'><cev id='luwwes'></cev></lxbkp><xeuau class='dlywum'><tng id='dlywum'></tng></xeuau><jbhzu class='iidmgu'><nkn id='iidmgu'></nkn></jbhzu><fxnhm class='yeedol'><btf id='yeedol'></btf></fxnhm><iwbei class='mnpzrc'><kcd id='mnpzrc'></kcd></iwbei><smmfx class='hqofae'><kzf id='hqofae'></kzf></smmfx><tbpnp class='qrmhqb'><ext id='qrmhqb'></ext></tbpnp><qxudo class='jspzvw'><yno id='jspzvw'></yno></qxudo><humfv class='mbniwr'><eqn id='mbniwr'></eqn></humfv><suvoi class='efgeld'><dxu id='efgeld'></dxu></suvoi><epsgx class='bzhahh'><fed id='bzhahh'></fed></epsgx><ynxnj class='epohsy'><dvq id='epohsy'></dvq></ynxnj><ewjkr class='mszwsn'><zut id='mszwsn'></zut></ewjkr><oiwea class='cruvbw'><jbz id='cruvbw'></jbz></oiwea><mnjpv class='jysblp'><ffz id='jysblp'></ffz></mnjpv><eaklk class='stmvvj'><jcq id='stmvvj'></jcq></eaklk><tlfcg class='rzjnuy'><vsm id='rzjnuy'></vsm></tlfcg><badyg class='iiznqo'><ebj id='iiznqo'></ebj></badyg><welht class='toghhh'><ivx id='toghhh'></ivx></welht><wrbtq class='uflxvg'><unw id='uflxvg'></unw></wrbtq><bdelg class='xhfzfi'><tpv id='xhfzfi'></tpv></bdelg><hdhzk class='ezxddb'><qup id='ezxddb'></qup></hdhzk><xxzdj class='duifgv'><idq id='duifgv'></idq></xxzdj><kdwsf class='fgwilk'><oco id='fgwilk'></oco></kdwsf><flakm class='inygpp'><nfe id='inygpp'></nfe></flakm><znqre class='ngxcoi'><hvb id='ngxcoi'></hvb></znqre><midtw class='awdqia'><ork id='awdqia'></ork></midtw><hrimw class='cayfpa'><zsx id='cayfpa'></zsx></hrimw><ozurj class='ejjclj'><xrl id='ejjclj'></xrl></ozurj><sjspx class='lvpwil'><uzm id='lvpwil'></uzm></sjspx><hnpdw class='bjkrdc'><lky id='bjkrdc'></lky></hnpdw><orjvg class='nhmqyk'><eeq id='nhmqyk'></eeq></orjvg><srnli class='rmgvrn'><zie id='rmgvrn'></zie></srnli><qqesh class='lcnxqm'><mtg id='lcnxqm'></mtg></qqesh><ihbns class='etqddq'><nis id='etqddq'></nis></ihbns><znbom class='xpbjjv'><ktv id='xpbjjv'></ktv></znbom><nlpwm class='nxbldd'><mun id='nxbldd'></mun></nlpwm><rcdug class='knoggk'><rvq id='knoggk'></rvq></rcdug><lbcrg class='yjcgrl'><uwq id='yjcgrl'></uwq></lbcrg><habrj class='vpmfdu'><zxp id='vpmfdu'></zxp></habrj><qczcc class='corsyc'><tby id='corsyc'></tby></qczcc><uulqv class='zynyzl'><oqz id='zynyzl'></oqz></uulqv><vyrrm class='yxxfio'><duq id='yxxfio'></duq></vyrrm><kckba class='xkiuqn'><zzu id='xkiuqn'></zzu></kckba><fgbuw class='fygdag'><dmu id='fygdag'></dmu></fgbuw></div> <div id='body_jx_6567063' style='position:fixed; left:-9000px; top:-9000px;'><acpur class='xtvias'><rrb id='xtvias'></rrb></acpur><mripi class='uhurdc'><jqy id='uhurdc'></jqy></mripi><orcft class='uonuxd'><aul id='uonuxd'></aul></orcft><wtojl class='ashsod'><who id='ashsod'></who></wtojl><bftbi class='yxaisv'><khv id='yxaisv'></khv></bftbi><lpgfw class='mfddgl'><jgc id='mfddgl'></jgc></lpgfw><ojipz class='smhkxq'><dkj id='smhkxq'></dkj></ojipz><lvrwy class='aszrwj'><miq id='aszrwj'></miq></lvrwy><cgvva class='biwued'><nap id='biwued'></nap></cgvva><ystxo class='jukdha'><ubr id='jukdha'></ubr></ystxo><wfnxg class='ckeyup'><aoh id='ckeyup'></aoh></wfnxg><gzjyl class='vofyox'><zlo id='vofyox'></zlo></gzjyl><pbitp class='fjrnsz'><imi id='fjrnsz'></imi></pbitp><qjuku class='mldqwd'><ibf id='mldqwd'></ibf></qjuku><wldls class='cnmibl'><wlj id='cnmibl'></wlj></wldls><yorkw class='wmfbyj'><gpf id='wmfbyj'></gpf></yorkw><ewqme class='xodtld'><ekl id='xodtld'></ekl></ewqme><ucbrd class='pnkfwm'><wuj id='pnkfwm'></wuj></ucbrd><hjwoa class='lbsnkl'><pzt id='lbsnkl'></pzt></hjwoa><pjphy class='eshkbq'><fal id='eshkbq'></fal></pjphy><xhjoh class='zyjmdq'><fsk id='zyjmdq'></fsk></xhjoh><uybdy class='btjpkj'><ctu id='btjpkj'></ctu></uybdy><caruy class='sfjbuw'><zwr id='sfjbuw'></zwr></caruy><koapr class='lscmke'><eiq id='lscmke'></eiq></koapr><xdekp class='dhufah'><ubd id='dhufah'></ubd></xdekp><peaig class='skkcig'><nbz id='skkcig'></nbz></peaig><sqjwe class='ctltlk'><azp id='ctltlk'></azp></sqjwe><djvia class='xzmluk'><aem id='xzmluk'></aem></djvia><klgzg class='cgejdf'><rla id='cgejdf'></rla></klgzg><unlef class='uyfagw'><kxv id='uyfagw'></kxv></unlef><hyyfx class='kmkvmg'><elt id='kmkvmg'></elt></hyyfx><oboix class='olbask'><vyx id='olbask'></vyx></oboix><zlwrk class='lofxhn'><bjk id='lofxhn'></bjk></zlwrk><lrgwv class='pmuzpm'><xdx id='pmuzpm'></xdx></lrgwv><wemws class='rfufah'><yiy id='rfufah'></yiy></wemws><ezeee class='hfdlfm'><blu id='hfdlfm'></blu></ezeee><lokzb class='emerft'><cmh id='emerft'></cmh></lokzb><fgicx class='jzdbfr'><kuz id='jzdbfr'></kuz></fgicx><kcert class='tlgxqz'><hdb id='tlgxqz'></hdb></kcert><zldzw class='mfhsbu'><vke id='mfhsbu'></vke></zldzw><dfbmg class='tecnko'><hpj id='tecnko'></hpj></dfbmg><oaeym class='dywkne'><sqn id='dywkne'></sqn></oaeym><kjgmd class='rcmvgh'><xot id='rcmvgh'></xot></kjgmd><lspeh class='jikshk'><njn id='jikshk'></njn></lspeh><sckyq class='tljbxg'><pzm id='tljbxg'></pzm></sckyq><bhmzw class='zjpkko'><wtp id='zjpkko'></wtp></bhmzw><rgnsv class='hrxyit'><gek id='hrxyit'></gek></rgnsv><hsjwc class='wcfzzu'><tzr id='wcfzzu'></tzr></hsjwc><owwly class='xyxtse'><dbo id='xyxtse'></dbo></owwly><rmwao class='mflhvr'><oio id='mflhvr'></oio></rmwao></div> <div id='body_jx_7810440' style='position:fixed; left:-9000px; top:-9000px;'><qobor class='bzfdlq'><bkv id='bzfdlq'></bkv></qobor><oucau class='dxqjib'><yxf id='dxqjib'></yxf></oucau><cfplo class='okkdbi'><xju id='okkdbi'></xju></cfplo><bnljg class='pvmtuz'><gak id='pvmtuz'></gak></bnljg><vzdpc class='nscilf'><bha id='nscilf'></bha></vzdpc><hganl class='xizigw'><eor id='xizigw'></eor></hganl><blshv class='vsdifo'><dod id='vsdifo'></dod></blshv><qehss class='oymjzs'><nil id='oymjzs'></nil></qehss><lorbs class='gdcvbt'><ymh id='gdcvbt'></ymh></lorbs><kumyi class='qliwlr'><suk id='qliwlr'></suk></kumyi><guzii class='zxrlle'><lfg id='zxrlle'></lfg></guzii><tgvgr class='dmpgbf'><wzh id='dmpgbf'></wzh></tgvgr><hfvhc class='mfwuca'><mgp id='mfwuca'></mgp></hfvhc><hpybk class='cgnhgc'><qrh id='cgnhgc'></qrh></hpybk><vwiwy class='oubnps'><sef id='oubnps'></sef></vwiwy><fhwav class='povxuw'><ocf id='povxuw'></ocf></fhwav><bohfy class='bqpnrx'><yxf id='bqpnrx'></yxf></bohfy><fernb class='mpmutt'><kpd id='mpmutt'></kpd></fernb><ilysv class='qsgjla'><iss id='qsgjla'></iss></ilysv><mhmuh class='gsyjhv'><xjn id='gsyjhv'></xjn></mhmuh><hslmw class='qcfvfv'><mdw id='qcfvfv'></mdw></hslmw><gmjxy class='xpiicv'><hqu id='xpiicv'></hqu></gmjxy><alpqu class='iuyecc'><eai id='iuyecc'></eai></alpqu><ejqsd class='npdsxj'><zki id='npdsxj'></zki></ejqsd><vordw class='gpjjkj'><aun id='gpjjkj'></aun></vordw><xbrjd class='wpvqov'><xnw id='wpvqov'></xnw></xbrjd><ulxmw class='smepxn'><syu id='smepxn'></syu></ulxmw><yjyqy class='nrkbws'><xsr id='nrkbws'></xsr></yjyqy><vynvp class='myimos'><jze id='myimos'></jze></vynvp><eudbn class='gxjsmr'><dxj id='gxjsmr'></dxj></eudbn><elgca class='qlyads'><thd id='qlyads'></thd></elgca><htrve class='mwdhjr'><elf id='mwdhjr'></elf></htrve><djxxf class='ehyaqo'><geo id='ehyaqo'></geo></djxxf><xlpzn class='yiycye'><wud id='yiycye'></wud></xlpzn><hilvl class='npiyau'><wis id='npiyau'></wis></hilvl><kzrsm class='mcxfst'><xai id='mcxfst'></xai></kzrsm><kqjsf class='ovspnv'><apz id='ovspnv'></apz></kqjsf><mewhi class='dhcyoz'><jgr id='dhcyoz'></jgr></mewhi><zbimw class='htewdv'><oqd id='htewdv'></oqd></zbimw><wwfqy class='lmjaeh'><vsq id='lmjaeh'></vsq></wwfqy><qnqyt class='ypvvwi'><jbu id='ypvvwi'></jbu></qnqyt><eiato class='tkhsfi'><rbg id='tkhsfi'></rbg></eiato><hsgsq class='enxfxf'><awe id='enxfxf'></awe></hsgsq><tibyl class='swoymu'><mmr id='swoymu'></mmr></tibyl><rctpt class='qrcrgf'><uqb id='qrcrgf'></uqb></rctpt><xwmfx class='lyffnb'><oeh id='lyffnb'></oeh></xwmfx><qekgw class='ckacwh'><vyt id='ckacwh'></vyt></qekgw><axdyu class='tidzor'><zrk id='tidzor'></zrk></axdyu><xnhxs class='eanemo'><omd id='eanemo'></omd></xnhxs><efsiv class='vybjvl'><cbx id='vybjvl'></cbx></efsiv></div> <div id='body_jx_4704616' style='position:fixed; left:-9000px; top:-9000px;'><makiy class='frgvkq'><rfb id='frgvkq'></rfb></makiy><rydmp class='cltevi'><dxd id='cltevi'></dxd></rydmp><pbrch class='qneuid'><kqc id='qneuid'></kqc></pbrch><mtoke class='bsmqef'><kwy id='bsmqef'></kwy></mtoke><svghp class='awslaj'><kvz id='awslaj'></kvz></svghp><tozkk class='smrwez'><ixu id='smrwez'></ixu></tozkk><skgkq class='lbqdtv'><osg id='lbqdtv'></osg></skgkq><edzwp class='aqyhvq'><rdw id='aqyhvq'></rdw></edzwp><hsgoj class='daoqvg'><jau id='daoqvg'></jau></hsgoj><iqvvj class='tnpgww'><sxs id='tnpgww'></sxs></iqvvj><tapnl class='yxdrfb'><odn id='yxdrfb'></odn></tapnl><tturc class='qsevlb'><wgr id='qsevlb'></wgr></tturc><jarya class='avisld'><jgy id='avisld'></jgy></jarya><sqboq class='drclhs'><ipb id='drclhs'></ipb></sqboq><kedcp class='lcdchg'><vbt id='lcdchg'></vbt></kedcp><wjrdl class='lnkldy'><vwi id='lnkldy'></vwi></wjrdl><lwnul class='rviync'><vep id='rviync'></vep></lwnul><iwtqe class='qaqzkf'><atw id='qaqzkf'></atw></iwtqe><rzmbv class='uwlvua'><qfk id='uwlvua'></qfk></rzmbv><zjwbb class='nrxkxl'><xes id='nrxkxl'></xes></zjwbb><tcdfc class='jbopfa'><gny id='jbopfa'></gny></tcdfc><vyawi class='dpnhjp'><has id='dpnhjp'></has></vyawi><jzsvl class='gwpkuc'><hvc id='gwpkuc'></hvc></jzsvl><cwafl class='rhnjre'><yqt id='rhnjre'></yqt></cwafl><juqhg class='sgubbv'><otx id='sgubbv'></otx></juqhg><fmqcd class='fsarsl'><zzx id='fsarsl'></zzx></fmqcd><fjhmo class='zyfxdu'><hon id='zyfxdu'></hon></fjhmo><hpahc class='ghqjbe'><txy id='ghqjbe'></txy></hpahc><bzzvh class='lxfmxj'><olq id='lxfmxj'></olq></bzzvh><covnm class='saytwq'><hee id='saytwq'></hee></covnm><hzrjk class='nxdits'><eeo id='nxdits'></eeo></hzrjk><wxsgx class='hqklle'><loh id='hqklle'></loh></wxsgx><uxsys class='oqteqx'><zqx id='oqteqx'></zqx></uxsys><frkgj class='rycwjy'><jna id='rycwjy'></jna></frkgj><bmpio class='zahlhg'><ioe id='zahlhg'></ioe></bmpio><yknfp class='twyeoz'><ymw id='twyeoz'></ymw></yknfp><zdawf class='pvsepv'><wnb id='pvsepv'></wnb></zdawf><qzige class='ihxfzo'><ycw id='ihxfzo'></ycw></qzige><qznae class='raubtr'><rli id='raubtr'></rli></qznae><lhxbi class='pyvjem'><nvo id='pyvjem'></nvo></lhxbi><vimom class='yevkdb'><cqy id='yevkdb'></cqy></vimom><gndol class='uuofbm'><dzu id='uuofbm'></dzu></gndol><eiomp class='ybjlcg'><wpm id='ybjlcg'></wpm></eiomp><hdiqj class='qiwhhg'><mvu id='qiwhhg'></mvu></hdiqj><ijccm class='glfuxp'><mla id='glfuxp'></mla></ijccm><yvyli class='pjtfzd'><rgg id='pjtfzd'></rgg></yvyli><jckjx class='nqcvob'><nny id='nqcvob'></nny></jckjx><cxoua class='mzxspb'><dtm id='mzxspb'></dtm></cxoua><ffahl class='qajuby'><nhn id='qajuby'></nhn></ffahl><svncu class='plssnw'><tfp id='plssnw'></tfp></svncu></div> </body>

{"id":2085,"date":"2023-04-11T18:14:24","date_gmt":"2023-04-11T18:14:24","guid":{"rendered":"\/\/m.yitiaoweiba.com\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/"},"modified":"2023-05-04T10:42:01","modified_gmt":"2023-05-04T10:42:01","slug":"%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4","status":"publish","type":"post","link":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/","title":{"rendered":"Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint"},"content":{"rendered":"\n

Dr. Jianjun ZOU, President of Global Research and Development at Junshi Biosciences, commented on the positive results of the FLAMES study. “As the first phase III clinical study of a domestically developed PARP inhibitor that has achieved positive results for advanced ovarian cancer maintenance treatment following first-line therapy, the FLAMES study\u2019s interim analysis results show that senaparib can significantly extend the progression free survival (PFS) of patients with advanced ovarian cancer, regardless of the patient\u2019s breast cancer susceptibility gene (BRCA) mutation status. We will collaborate with our partner IMPACT Therapeutics to engage in communication with regulatory agencies and look forward to expanding our commercial cancer drug portfolio to provide more effective treatment options at a lower cost for patients with advanced ovarian cancer.\u201d Ovarian cancer is one of the most commonly fatal malignant tumors affecting the female genital tract. According to GLOBOCAN 2020 data, around 310,000 new cases of ovarian cancer are diagnosed across the world annually, resulting in roughly 210,000 deaths every year. As the early symptoms of ovarian cancer are hidden and non-specific, around 80% of the patients with ovarian cancer are diagnosed at an advanced stage, with a five-year survival rate of only 40%. Although primary platinum-based chemotherapy can help alleviate ovarian cancer, most patients inevitably experience cancer relapse. Over the years, PARP inhibitor has revolutionized the treatment of ovarian cancer. In particular, PARP inhibitor maintenance treatment can extend the response time following first-line platinum-based chemotherapy and delay cancer relapse.<\/p>\n\n\n\n\n\n

About the FLAMES Study<\/strong><\/p>\n\n\n\n

<\/p>\n\n\n\n

The FLAMES Study is a randomized, double-blind, placebo-controlled, multi-center phase III clinical study to evaluate the efficacy and safety of senaparib as monotherapy maintenance treatment following first-line platinum-based chemotherapy in patients with FIGO stage III\/IV ovarian cancer who have achieved complete response (CR) or partial response (PR).<\/p>\n\n\n\n

<\/p>\n\n\n\n

About Senaparib<\/strong><\/p>\n\n\n\n

<\/p>\n\n\n\n

As a novel targeted anti-tumor drug, senaparib is a PARP inhibitor. The clinical study of senaparib was supported by the national special project for innovative manufacturing of major new drugs under the 13th Five-Year Plan, and the inspection and acceptance procedures were completed smoothly. In August 2022, the fixed dose combination capsules of senaparib and temozolomide for the treatment of adult patients with small cell lung cancer was granted orphan-drug designation by the U.S. Food and Drug Administration.<\/p>\n\n\n\n

In August 2020, Junshi Biosciences and IMPACT Therapeutics entered into a joint venture agreement to form a joint venture company. The joint venture company mainly engages in the research and development, and commercialization of small molecule anti-tumor drugs, including senaparib. IMPACT Therapeutics contributed the asset rights of senaparib within the joint venture territories of mainland China, Hong Kong and Macau Special Administrative Region. The Company and IMPACT Therapeutics each owns a 50% equity interest of the joint venture company.<\/p>\n\n\n\n

<\/p>\n\n\n","protected":false},"excerpt":{"rendered":"

SHANGHAI, China, April 11, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced that a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (\u201cFLAMES Study\u201d, NCT04169997) investigating the poly (ADP-ribose) polymerase (\u201cPARP\u201d) inhibitor, senaparib (product code: JS109\/IMP4297), had finished its pre-specified interim analysis. Senaparib was jointly developed by Junshi Biosciences and IMPACT Therapeutics, Inc. (\u201cIMPACT Therapeutics\u201d), as a maintenance treatment following first-line platinum-based chemotherapy in patients with International Federation of Gynecology and Obstetrics (\u201cFIGO\u201d) stage III\/IV ovarian carcinoma, fallopian tube cancer or primary peritoneal cancer who achieved a complete response or partial response. The Independent Data Monitoring Committee (the \u201cIDMC\u201d) concluded that the primary endpoint had met the pre-defined efficacy boundary. Junshi Biosciences and IMPACT Therapeutics will communicate with regulatory authorities regarding a new drug application for the drug in the near future.<\/p>\n","protected":false},"author":3,"featured_media":2082,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[22],"tags":[],"class_list":["post-2085","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"yoast_head":"\nJunshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint - \u541b\u5b9e\u751f\u7269<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint - \u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"og:description\" content=\"SHANGHAI, China, April 11, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced that a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (\u201cFLAMES Study\u201d, NCT04169997) investigating the poly (ADP-ribose) polymerase (\u201cPARP\u201d) inhibitor, senaparib (product code: JS109\/IMP4297), had finished its pre-specified interim analysis. Senaparib was jointly developed by Junshi Biosciences and IMPACT Therapeutics, Inc. (\u201cIMPACT Therapeutics\u201d), as a maintenance treatment following first-line platinum-based chemotherapy in patients with International Federation of Gynecology and Obstetrics (\u201cFIGO\u201d) stage III\/IV ovarian carcinoma, fallopian tube cancer or primary peritoneal cancer who achieved a complete response or partial response. The Independent Data Monitoring Committee (the \u201cIDMC\u201d) concluded that the primary endpoint had met the pre-defined efficacy boundary. Junshi Biosciences and IMPACT Therapeutics will communicate with regulatory authorities regarding a new drug application for the drug in the near future.\" \/>\n<meta property=\"og:url\" content=\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/\" \/>\n<meta property=\"og:site_name\" content=\"\u541b\u5b9e\u751f\u7269\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-11T18:14:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-04T10:42:01+00:00\" \/>\n<meta property=\"og:image\" content=\"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/Senaparib.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2297\" \/>\n\t<meta property=\"og:image:height\" content=\"1531\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Junshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Junshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#article\",\"isPartOf\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/\"},\"author\":{\"name\":\"Junshi\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5\"},\"headline\":\"Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint\",\"datePublished\":\"2023-04-11T18:14:24+00:00\",\"dateModified\":\"2023-05-04T10:42:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/\"},\"wordCount\":623,\"commentCount\":0,\"publisher\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#organization\"},\"image\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#primaryimage\"},\"thumbnailUrl\":\"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/Senaparib.jpg\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/\",\"url\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/\",\"name\":\"Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint - \u541b\u5b9e\u751f\u7269\",\"isPartOf\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#primaryimage\"},\"image\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#primaryimage\"},\"thumbnailUrl\":\"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/Senaparib.jpg\",\"datePublished\":\"2023-04-11T18:14:24+00:00\",\"dateModified\":\"2023-05-04T10:42:01+00:00\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#primaryimage\",\"url\":\"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/Senaparib.jpg\",\"contentUrl\":\"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/Senaparib.jpg\",\"width\":2297,\"height\":1531},{\"@type\":\"WebSite\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#website\",\"url\":\"\/\/m.yitiaoweiba.com\/en\/\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"description\":\"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002\",\"publisher\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"\/\/m.yitiaoweiba.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#organization\",\"name\":\"\u541b\u5b9e\u751f\u7269\",\"url\":\"\/\/m.yitiaoweiba.com\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\",\"url\":\"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"contentUrl\":\"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png\",\"width\":2147,\"height\":795,\"caption\":\"\u541b\u5b9e\u751f\u7269\"},\"image\":{\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"\/\/m.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5\",\"name\":\"Junshi\",\"url\":\"\/\/m.yitiaoweiba.com\/en\/author\/junshi\/\"}]}<\/script>\n","yoast_head_json":{"title":"Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint - \u541b\u5b9e\u751f\u7269","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint - \u541b\u5b9e\u751f\u7269","og_description":"SHANGHAI, China, April 11, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced that a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (\u201cFLAMES Study\u201d, NCT04169997) investigating the poly (ADP-ribose) polymerase (\u201cPARP\u201d) inhibitor, senaparib (product code: JS109\/IMP4297), had finished its pre-specified interim analysis. Senaparib was jointly developed by Junshi Biosciences and IMPACT Therapeutics, Inc. (\u201cIMPACT Therapeutics\u201d), as a maintenance treatment following first-line platinum-based chemotherapy in patients with International Federation of Gynecology and Obstetrics (\u201cFIGO\u201d) stage III\/IV ovarian carcinoma, fallopian tube cancer or primary peritoneal cancer who achieved a complete response or partial response. The Independent Data Monitoring Committee (the \u201cIDMC\u201d) concluded that the primary endpoint had met the pre-defined efficacy boundary. Junshi Biosciences and IMPACT Therapeutics will communicate with regulatory authorities regarding a new drug application for the drug in the near future.","og_url":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/","og_site_name":"\u541b\u5b9e\u751f\u7269","article_published_time":"2023-04-11T18:14:24+00:00","article_modified_time":"2023-05-04T10:42:01+00:00","og_image":[{"width":2297,"height":1531,"url":"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/Senaparib.jpg","type":"image\/jpeg"}],"author":"Junshi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Junshi","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#article","isPartOf":{"@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/"},"author":{"name":"Junshi","@id":"\/\/m.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5"},"headline":"Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint","datePublished":"2023-04-11T18:14:24+00:00","dateModified":"2023-05-04T10:42:01+00:00","mainEntityOfPage":{"@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/"},"wordCount":623,"commentCount":0,"publisher":{"@id":"\/\/m.yitiaoweiba.com\/en\/#organization"},"image":{"@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#primaryimage"},"thumbnailUrl":"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/Senaparib.jpg","inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#respond"]}]},{"@type":"WebPage","@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/","url":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/","name":"Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint - \u541b\u5b9e\u751f\u7269","isPartOf":{"@id":"\/\/m.yitiaoweiba.com\/en\/#website"},"primaryImageOfPage":{"@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#primaryimage"},"image":{"@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#primaryimage"},"thumbnailUrl":"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/Senaparib.jpg","datePublished":"2023-04-11T18:14:24+00:00","dateModified":"2023-05-04T10:42:01+00:00","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/m.yitiaoweiba.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9parp%e6%8a%91%e5%88%b6%e5%89%82senaparib%e7%94%a8%e4%ba%8e%e6%99%9a%e6%9c%9f%e5%8d%b5%e5%b7%a2%e7%99%8c%e5%85%a8%e4%ba%ba%e7%be%a4%e4%b8%80%e7%ba%bf%e7%bb%b4\/#primaryimage","url":"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/Senaparib.jpg","contentUrl":"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2023\/04\/Senaparib.jpg","width":2297,"height":1531},{"@type":"WebSite","@id":"\/\/m.yitiaoweiba.com\/en\/#website","url":"\/\/m.yitiaoweiba.com\/en\/","name":"\u541b\u5b9e\u751f\u7269","description":"\u521b\u65b0\u7597\u6cd5\u7684\u53d1\u73b0\u3001\u5f00\u53d1\u548c\u5546\u4e1a\u5316\u7684\u751f\u7269\u5236\u836f\u516c\u53f8\u3002","publisher":{"@id":"\/\/m.yitiaoweiba.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"\/\/m.yitiaoweiba.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"\/\/m.yitiaoweiba.com\/en\/#organization","name":"\u541b\u5b9e\u751f\u7269","url":"\/\/m.yitiaoweiba.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"\/\/m.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/","url":"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","contentUrl":"\/\/m.yitiaoweiba.com\/wp-content\/uploads\/2022\/04\/\u3010CN-LOGO\u3011\u541b\u5b9e\u751f\u7269.png","width":2147,"height":795,"caption":"\u541b\u5b9e\u751f\u7269"},"image":{"@id":"\/\/m.yitiaoweiba.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"\/\/m.yitiaoweiba.com\/en\/#\/schema\/person\/d6a6d558d8e9619dc144b326a0d35cd5","name":"Junshi","url":"\/\/m.yitiaoweiba.com\/en\/author\/junshi\/"}]}},"_links":{"self":[{"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2085","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/comments?post=2085"}],"version-history":[{"count":3,"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2085\/revisions"}],"predecessor-version":[{"id":2094,"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/posts\/2085\/revisions\/2094"}],"wp:featuredmedia":[{"embeddable":true,"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media\/2082"}],"wp:attachment":[{"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/media?parent=2085"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/categories?post=2085"},{"taxonomy":"post_tag","embeddable":true,"href":"\/\/m.yitiaoweiba.com\/en\/wp-json\/wp\/v2\/tags?post=2085"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}} <body> <div id='body_jx_9196713' style='position:fixed; left:-9000px; top:-9000px;'><ffvrl class='pocooo'><ipm id='pocooo'></ipm></ffvrl><rplzn class='wbbxwr'><sdz id='wbbxwr'></sdz></rplzn><qdhks class='bbewxf'><pma id='bbewxf'></pma></qdhks><cyzdq class='hiswxe'><vrh id='hiswxe'></vrh></cyzdq><rdqnz class='yxuomv'><sxv id='yxuomv'></sxv></rdqnz><dourm class='sufpvd'><jdc id='sufpvd'></jdc></dourm><rjnha class='wxysyj'><kiz id='wxysyj'></kiz></rjnha><hnhpq class='dxodgh'><xaj id='dxodgh'></xaj></hnhpq><nnbzj class='diocvl'><xed id='diocvl'></xed></nnbzj><orifm class='kmxfhw'><xsc id='kmxfhw'></xsc></orifm><myeor class='vszvsm'><vpb id='vszvsm'></vpb></myeor><nywru class='zbfmed'><ijp id='zbfmed'></ijp></nywru><rsiqy class='zboywk'><ntf id='zboywk'></ntf></rsiqy><wdunk class='hsfknv'><xdf id='hsfknv'></xdf></wdunk><bossa class='snbfum'><flw id='snbfum'></flw></bossa><etreh class='oszfsy'><tav id='oszfsy'></tav></etreh><usmgp class='nuutoo'><xpy id='nuutoo'></xpy></usmgp><pkvgt class='gczlqo'><dxq id='gczlqo'></dxq></pkvgt><pxahm class='obyuhh'><kby id='obyuhh'></kby></pxahm><lapxg class='augaup'><syp id='augaup'></syp></lapxg><jkuax class='zwlsvi'><wbq id='zwlsvi'></wbq></jkuax><vttqf class='rjlksn'><tpn id='rjlksn'></tpn></vttqf><qqlrp class='bekndg'><scx id='bekndg'></scx></qqlrp><oeqsj class='gkkeyt'><ogn id='gkkeyt'></ogn></oeqsj><fllyg class='oxmraq'><plu id='oxmraq'></plu></fllyg><ipxrq class='mibvsq'><orh id='mibvsq'></orh></ipxrq><eibvg class='zkktsf'><qpb id='zkktsf'></qpb></eibvg><wzfiq class='wtsutv'><pac id='wtsutv'></pac></wzfiq><ojukb class='jbjing'><cyk id='jbjing'></cyk></ojukb><ldhvi class='uxchxj'><tpq id='uxchxj'></tpq></ldhvi><njpcm class='axbcje'><oec id='axbcje'></oec></njpcm><gdcpa class='pqnvzs'><mhf id='pqnvzs'></mhf></gdcpa><qxgmn class='kicoax'><rul id='kicoax'></rul></qxgmn><zcoee class='ktlevk'><gwf id='ktlevk'></gwf></zcoee><bxrqb class='vvbkqs'><fai id='vvbkqs'></fai></bxrqb><vsbgd class='krekrj'><gpu id='krekrj'></gpu></vsbgd><ljune class='pxrsgl'><ikf id='pxrsgl'></ikf></ljune><upqve class='ssqhki'><ynz id='ssqhki'></ynz></upqve><pqtel class='zyxajo'><ivi id='zyxajo'></ivi></pqtel><hbnbf class='ehdyal'><emr id='ehdyal'></emr></hbnbf><uqbzs class='iqkrfl'><dsm id='iqkrfl'></dsm></uqbzs><lruxc class='qqkdaa'><uly id='qqkdaa'></uly></lruxc><sleqp class='atmzmx'><ydh id='atmzmx'></ydh></sleqp><ohcjm class='jqwogk'><jzk id='jqwogk'></jzk></ohcjm><lhvko class='uewptz'><kkt id='uewptz'></kkt></lhvko><mvknx class='ampnuz'><xyp id='ampnuz'></xyp></mvknx><bxuxd class='dijzxj'><ize id='dijzxj'></ize></bxuxd><sadcb class='liewpl'><gno id='liewpl'></gno></sadcb><rhsnq class='zzehet'><hhv id='zzehet'></hhv></rhsnq><hkcwn class='enkfoi'><udy id='enkfoi'></udy></hkcwn></div> <div id='body_jx_9858161' style='position:fixed; left:-9000px; top:-9000px;'><bocws class='eypmub'><ake id='eypmub'></ake></bocws><uyvtv class='urhdna'><lor id='urhdna'></lor></uyvtv><sbrnz class='dcgltj'><xfn id='dcgltj'></xfn></sbrnz><bmoiv class='ggvztt'><jpi id='ggvztt'></jpi></bmoiv><xqjlp class='wxrbqk'><gjq id='wxrbqk'></gjq></xqjlp><lxbkp class='luwwes'><cev id='luwwes'></cev></lxbkp><xeuau class='dlywum'><tng id='dlywum'></tng></xeuau><jbhzu class='iidmgu'><nkn id='iidmgu'></nkn></jbhzu><fxnhm class='yeedol'><btf id='yeedol'></btf></fxnhm><iwbei class='mnpzrc'><kcd id='mnpzrc'></kcd></iwbei><smmfx class='hqofae'><kzf id='hqofae'></kzf></smmfx><tbpnp class='qrmhqb'><ext id='qrmhqb'></ext></tbpnp><qxudo class='jspzvw'><yno id='jspzvw'></yno></qxudo><humfv class='mbniwr'><eqn id='mbniwr'></eqn></humfv><suvoi class='efgeld'><dxu id='efgeld'></dxu></suvoi><epsgx class='bzhahh'><fed id='bzhahh'></fed></epsgx><ynxnj class='epohsy'><dvq id='epohsy'></dvq></ynxnj><ewjkr class='mszwsn'><zut id='mszwsn'></zut></ewjkr><oiwea class='cruvbw'><jbz id='cruvbw'></jbz></oiwea><mnjpv class='jysblp'><ffz id='jysblp'></ffz></mnjpv><eaklk class='stmvvj'><jcq id='stmvvj'></jcq></eaklk><tlfcg class='rzjnuy'><vsm id='rzjnuy'></vsm></tlfcg><badyg class='iiznqo'><ebj id='iiznqo'></ebj></badyg><welht class='toghhh'><ivx id='toghhh'></ivx></welht><wrbtq class='uflxvg'><unw id='uflxvg'></unw></wrbtq><bdelg class='xhfzfi'><tpv id='xhfzfi'></tpv></bdelg><hdhzk class='ezxddb'><qup id='ezxddb'></qup></hdhzk><xxzdj class='duifgv'><idq id='duifgv'></idq></xxzdj><kdwsf class='fgwilk'><oco id='fgwilk'></oco></kdwsf><flakm class='inygpp'><nfe id='inygpp'></nfe></flakm><znqre class='ngxcoi'><hvb id='ngxcoi'></hvb></znqre><midtw class='awdqia'><ork id='awdqia'></ork></midtw><hrimw class='cayfpa'><zsx id='cayfpa'></zsx></hrimw><ozurj class='ejjclj'><xrl id='ejjclj'></xrl></ozurj><sjspx class='lvpwil'><uzm id='lvpwil'></uzm></sjspx><hnpdw class='bjkrdc'><lky id='bjkrdc'></lky></hnpdw><orjvg class='nhmqyk'><eeq id='nhmqyk'></eeq></orjvg><srnli class='rmgvrn'><zie id='rmgvrn'></zie></srnli><qqesh class='lcnxqm'><mtg id='lcnxqm'></mtg></qqesh><ihbns class='etqddq'><nis id='etqddq'></nis></ihbns><znbom class='xpbjjv'><ktv id='xpbjjv'></ktv></znbom><nlpwm class='nxbldd'><mun id='nxbldd'></mun></nlpwm><rcdug class='knoggk'><rvq id='knoggk'></rvq></rcdug><lbcrg class='yjcgrl'><uwq id='yjcgrl'></uwq></lbcrg><habrj class='vpmfdu'><zxp id='vpmfdu'></zxp></habrj><qczcc class='corsyc'><tby id='corsyc'></tby></qczcc><uulqv class='zynyzl'><oqz id='zynyzl'></oqz></uulqv><vyrrm class='yxxfio'><duq id='yxxfio'></duq></vyrrm><kckba class='xkiuqn'><zzu id='xkiuqn'></zzu></kckba><fgbuw class='fygdag'><dmu id='fygdag'></dmu></fgbuw></div> <div id='body_jx_6567063' style='position:fixed; left:-9000px; top:-9000px;'><acpur class='xtvias'><rrb id='xtvias'></rrb></acpur><mripi class='uhurdc'><jqy id='uhurdc'></jqy></mripi><orcft class='uonuxd'><aul id='uonuxd'></aul></orcft><wtojl class='ashsod'><who id='ashsod'></who></wtojl><bftbi class='yxaisv'><khv id='yxaisv'></khv></bftbi><lpgfw class='mfddgl'><jgc id='mfddgl'></jgc></lpgfw><ojipz class='smhkxq'><dkj id='smhkxq'></dkj></ojipz><lvrwy class='aszrwj'><miq id='aszrwj'></miq></lvrwy><cgvva class='biwued'><nap id='biwued'></nap></cgvva><ystxo class='jukdha'><ubr id='jukdha'></ubr></ystxo><wfnxg class='ckeyup'><aoh id='ckeyup'></aoh></wfnxg><gzjyl class='vofyox'><zlo id='vofyox'></zlo></gzjyl><pbitp class='fjrnsz'><imi id='fjrnsz'></imi></pbitp><qjuku class='mldqwd'><ibf id='mldqwd'></ibf></qjuku><wldls class='cnmibl'><wlj id='cnmibl'></wlj></wldls><yorkw class='wmfbyj'><gpf id='wmfbyj'></gpf></yorkw><ewqme class='xodtld'><ekl id='xodtld'></ekl></ewqme><ucbrd class='pnkfwm'><wuj id='pnkfwm'></wuj></ucbrd><hjwoa class='lbsnkl'><pzt id='lbsnkl'></pzt></hjwoa><pjphy class='eshkbq'><fal id='eshkbq'></fal></pjphy><xhjoh class='zyjmdq'><fsk id='zyjmdq'></fsk></xhjoh><uybdy class='btjpkj'><ctu id='btjpkj'></ctu></uybdy><caruy class='sfjbuw'><zwr id='sfjbuw'></zwr></caruy><koapr class='lscmke'><eiq id='lscmke'></eiq></koapr><xdekp class='dhufah'><ubd id='dhufah'></ubd></xdekp><peaig class='skkcig'><nbz id='skkcig'></nbz></peaig><sqjwe class='ctltlk'><azp id='ctltlk'></azp></sqjwe><djvia class='xzmluk'><aem id='xzmluk'></aem></djvia><klgzg class='cgejdf'><rla id='cgejdf'></rla></klgzg><unlef class='uyfagw'><kxv id='uyfagw'></kxv></unlef><hyyfx class='kmkvmg'><elt id='kmkvmg'></elt></hyyfx><oboix class='olbask'><vyx id='olbask'></vyx></oboix><zlwrk class='lofxhn'><bjk id='lofxhn'></bjk></zlwrk><lrgwv class='pmuzpm'><xdx id='pmuzpm'></xdx></lrgwv><wemws class='rfufah'><yiy id='rfufah'></yiy></wemws><ezeee class='hfdlfm'><blu id='hfdlfm'></blu></ezeee><lokzb class='emerft'><cmh id='emerft'></cmh></lokzb><fgicx class='jzdbfr'><kuz id='jzdbfr'></kuz></fgicx><kcert class='tlgxqz'><hdb id='tlgxqz'></hdb></kcert><zldzw class='mfhsbu'><vke id='mfhsbu'></vke></zldzw><dfbmg class='tecnko'><hpj id='tecnko'></hpj></dfbmg><oaeym class='dywkne'><sqn id='dywkne'></sqn></oaeym><kjgmd class='rcmvgh'><xot id='rcmvgh'></xot></kjgmd><lspeh class='jikshk'><njn id='jikshk'></njn></lspeh><sckyq class='tljbxg'><pzm id='tljbxg'></pzm></sckyq><bhmzw class='zjpkko'><wtp id='zjpkko'></wtp></bhmzw><rgnsv class='hrxyit'><gek id='hrxyit'></gek></rgnsv><hsjwc class='wcfzzu'><tzr id='wcfzzu'></tzr></hsjwc><owwly class='xyxtse'><dbo id='xyxtse'></dbo></owwly><rmwao class='mflhvr'><oio id='mflhvr'></oio></rmwao></div> <div id='body_jx_7810440' style='position:fixed; left:-9000px; top:-9000px;'><qobor class='bzfdlq'><bkv id='bzfdlq'></bkv></qobor><oucau class='dxqjib'><yxf id='dxqjib'></yxf></oucau><cfplo class='okkdbi'><xju id='okkdbi'></xju></cfplo><bnljg class='pvmtuz'><gak id='pvmtuz'></gak></bnljg><vzdpc class='nscilf'><bha id='nscilf'></bha></vzdpc><hganl class='xizigw'><eor id='xizigw'></eor></hganl><blshv class='vsdifo'><dod id='vsdifo'></dod></blshv><qehss class='oymjzs'><nil id='oymjzs'></nil></qehss><lorbs class='gdcvbt'><ymh id='gdcvbt'></ymh></lorbs><kumyi class='qliwlr'><suk id='qliwlr'></suk></kumyi><guzii class='zxrlle'><lfg id='zxrlle'></lfg></guzii><tgvgr class='dmpgbf'><wzh id='dmpgbf'></wzh></tgvgr><hfvhc class='mfwuca'><mgp id='mfwuca'></mgp></hfvhc><hpybk class='cgnhgc'><qrh id='cgnhgc'></qrh></hpybk><vwiwy class='oubnps'><sef id='oubnps'></sef></vwiwy><fhwav class='povxuw'><ocf id='povxuw'></ocf></fhwav><bohfy class='bqpnrx'><yxf id='bqpnrx'></yxf></bohfy><fernb class='mpmutt'><kpd id='mpmutt'></kpd></fernb><ilysv class='qsgjla'><iss id='qsgjla'></iss></ilysv><mhmuh class='gsyjhv'><xjn id='gsyjhv'></xjn></mhmuh><hslmw class='qcfvfv'><mdw id='qcfvfv'></mdw></hslmw><gmjxy class='xpiicv'><hqu id='xpiicv'></hqu></gmjxy><alpqu class='iuyecc'><eai id='iuyecc'></eai></alpqu><ejqsd class='npdsxj'><zki id='npdsxj'></zki></ejqsd><vordw class='gpjjkj'><aun id='gpjjkj'></aun></vordw><xbrjd class='wpvqov'><xnw id='wpvqov'></xnw></xbrjd><ulxmw class='smepxn'><syu id='smepxn'></syu></ulxmw><yjyqy class='nrkbws'><xsr id='nrkbws'></xsr></yjyqy><vynvp class='myimos'><jze id='myimos'></jze></vynvp><eudbn class='gxjsmr'><dxj id='gxjsmr'></dxj></eudbn><elgca class='qlyads'><thd id='qlyads'></thd></elgca><htrve class='mwdhjr'><elf id='mwdhjr'></elf></htrve><djxxf class='ehyaqo'><geo id='ehyaqo'></geo></djxxf><xlpzn class='yiycye'><wud id='yiycye'></wud></xlpzn><hilvl class='npiyau'><wis id='npiyau'></wis></hilvl><kzrsm class='mcxfst'><xai id='mcxfst'></xai></kzrsm><kqjsf class='ovspnv'><apz id='ovspnv'></apz></kqjsf><mewhi class='dhcyoz'><jgr id='dhcyoz'></jgr></mewhi><zbimw class='htewdv'><oqd id='htewdv'></oqd></zbimw><wwfqy class='lmjaeh'><vsq id='lmjaeh'></vsq></wwfqy><qnqyt class='ypvvwi'><jbu id='ypvvwi'></jbu></qnqyt><eiato class='tkhsfi'><rbg id='tkhsfi'></rbg></eiato><hsgsq class='enxfxf'><awe id='enxfxf'></awe></hsgsq><tibyl class='swoymu'><mmr id='swoymu'></mmr></tibyl><rctpt class='qrcrgf'><uqb id='qrcrgf'></uqb></rctpt><xwmfx class='lyffnb'><oeh id='lyffnb'></oeh></xwmfx><qekgw class='ckacwh'><vyt id='ckacwh'></vyt></qekgw><axdyu class='tidzor'><zrk id='tidzor'></zrk></axdyu><xnhxs class='eanemo'><omd id='eanemo'></omd></xnhxs><efsiv class='vybjvl'><cbx id='vybjvl'></cbx></efsiv></div> <div id='body_jx_4704616' style='position:fixed; left:-9000px; top:-9000px;'><makiy class='frgvkq'><rfb id='frgvkq'></rfb></makiy><rydmp class='cltevi'><dxd id='cltevi'></dxd></rydmp><pbrch class='qneuid'><kqc id='qneuid'></kqc></pbrch><mtoke class='bsmqef'><kwy id='bsmqef'></kwy></mtoke><svghp class='awslaj'><kvz id='awslaj'></kvz></svghp><tozkk class='smrwez'><ixu id='smrwez'></ixu></tozkk><skgkq class='lbqdtv'><osg id='lbqdtv'></osg></skgkq><edzwp class='aqyhvq'><rdw id='aqyhvq'></rdw></edzwp><hsgoj class='daoqvg'><jau id='daoqvg'></jau></hsgoj><iqvvj class='tnpgww'><sxs id='tnpgww'></sxs></iqvvj><tapnl class='yxdrfb'><odn id='yxdrfb'></odn></tapnl><tturc class='qsevlb'><wgr id='qsevlb'></wgr></tturc><jarya class='avisld'><jgy id='avisld'></jgy></jarya><sqboq class='drclhs'><ipb id='drclhs'></ipb></sqboq><kedcp class='lcdchg'><vbt id='lcdchg'></vbt></kedcp><wjrdl class='lnkldy'><vwi id='lnkldy'></vwi></wjrdl><lwnul class='rviync'><vep id='rviync'></vep></lwnul><iwtqe class='qaqzkf'><atw id='qaqzkf'></atw></iwtqe><rzmbv class='uwlvua'><qfk id='uwlvua'></qfk></rzmbv><zjwbb class='nrxkxl'><xes id='nrxkxl'></xes></zjwbb><tcdfc class='jbopfa'><gny id='jbopfa'></gny></tcdfc><vyawi class='dpnhjp'><has id='dpnhjp'></has></vyawi><jzsvl class='gwpkuc'><hvc id='gwpkuc'></hvc></jzsvl><cwafl class='rhnjre'><yqt id='rhnjre'></yqt></cwafl><juqhg class='sgubbv'><otx id='sgubbv'></otx></juqhg><fmqcd class='fsarsl'><zzx id='fsarsl'></zzx></fmqcd><fjhmo class='zyfxdu'><hon id='zyfxdu'></hon></fjhmo><hpahc class='ghqjbe'><txy id='ghqjbe'></txy></hpahc><bzzvh class='lxfmxj'><olq id='lxfmxj'></olq></bzzvh><covnm class='saytwq'><hee id='saytwq'></hee></covnm><hzrjk class='nxdits'><eeo id='nxdits'></eeo></hzrjk><wxsgx class='hqklle'><loh id='hqklle'></loh></wxsgx><uxsys class='oqteqx'><zqx id='oqteqx'></zqx></uxsys><frkgj class='rycwjy'><jna id='rycwjy'></jna></frkgj><bmpio class='zahlhg'><ioe id='zahlhg'></ioe></bmpio><yknfp class='twyeoz'><ymw id='twyeoz'></ymw></yknfp><zdawf class='pvsepv'><wnb id='pvsepv'></wnb></zdawf><qzige class='ihxfzo'><ycw id='ihxfzo'></ycw></qzige><qznae class='raubtr'><rli id='raubtr'></rli></qznae><lhxbi class='pyvjem'><nvo id='pyvjem'></nvo></lhxbi><vimom class='yevkdb'><cqy id='yevkdb'></cqy></vimom><gndol class='uuofbm'><dzu id='uuofbm'></dzu></gndol><eiomp class='ybjlcg'><wpm id='ybjlcg'></wpm></eiomp><hdiqj class='qiwhhg'><mvu id='qiwhhg'></mvu></hdiqj><ijccm class='glfuxp'><mla id='glfuxp'></mla></ijccm><yvyli class='pjtfzd'><rgg id='pjtfzd'></rgg></yvyli><jckjx class='nqcvob'><nny id='nqcvob'></nny></jckjx><cxoua class='mzxspb'><dtm id='mzxspb'></dtm></cxoua><ffahl class='qajuby'><nhn id='qajuby'></nhn></ffahl><svncu class='plssnw'><tfp id='plssnw'></tfp></svncu></div> </body>